novo nordisk oral semaglutide fda approval has announced that the has approved the Wegovy® pill (once-daily 25 mg) as the first ever oral GLP-1 receptor agonist therapy for chronic weight management in adults Novo says it's submitted obesity

The evidence to date seems pretty clear that Ozempic can be a great tool for those with type 2 diabetes

GLP-1 (glucagon-like peptide-1) is a hormone produced in the intestines that is vital for regulating blood sugar levels and appetite

L o w blood sugar (hypoglycemia): If you take JARDIANCE with another medicine that can cause low blood sugar, such as sulfonylurea or insulin, your risk of low blood sugar is higher

Other early side effects may include: Injection site reactions (redness, itching, bruising) usually mild and transient Headache Common Most gastrointestinal side effects are mild to moderate in severity and tend to diminish as the body adapts to the medication

The mechanisms that caused initial weight gain remain present, and appetite typically returns to pre-treatment levels within weeks of discontinuation